ATXS vs. LRMR, TVTX, IGMS, TRDA, HRTX, KALV, OLMA, APLT, OCS, and FULC
Should you be buying Astria Therapeutics stock or one of its competitors? The main competitors of Astria Therapeutics include Larimar Therapeutics (LRMR), Travere Therapeutics (TVTX), IGM Biosciences (IGMS), Entrada Therapeutics (TRDA), Heron Therapeutics (HRTX), KalVista Pharmaceuticals (KALV), Olema Pharmaceuticals (OLMA), Applied Therapeutics (APLT), Oculis (OCS), and Fulcrum Therapeutics (FULC). These companies are all part of the "pharmaceutical preparations" industry.
Larimar Therapeutics (NASDAQ:LRMR) and Astria Therapeutics (NASDAQ:ATXS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, media sentiment, community ranking, risk, institutional ownership and earnings.
91.9% of Larimar Therapeutics shares are held by institutional investors. Comparatively, 99.0% of Astria Therapeutics shares are held by institutional investors. 4.3% of Larimar Therapeutics shares are held by insiders. Comparatively, 2.9% of Astria Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
In the previous week, Larimar Therapeutics had 2 more articles in the media than Astria Therapeutics. MarketBeat recorded 9 mentions for Larimar Therapeutics and 7 mentions for Astria Therapeutics. Astria Therapeutics' average media sentiment score of 0.70 beat Larimar Therapeutics' score of 0.48 indicating that Larimar Therapeutics is being referred to more favorably in the media.
Larimar Therapeutics has a beta of 0.96, suggesting that its stock price is 4% less volatile than the S&P 500. Comparatively, Astria Therapeutics has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500.
Astria Therapeutics received 526 more outperform votes than Larimar Therapeutics when rated by MarketBeat users. Likewise, 72.58% of users gave Astria Therapeutics an outperform vote while only 62.50% of users gave Larimar Therapeutics an outperform vote.
Larimar Therapeutics is trading at a lower price-to-earnings ratio than Astria Therapeutics, indicating that it is currently the more affordable of the two stocks.
Larimar Therapeutics currently has a consensus target price of $21.33, indicating a potential upside of 189.07%. Astria Therapeutics has a consensus target price of $22.50, indicating a potential upside of 148.62%. Given Astria Therapeutics' higher probable upside, research analysts clearly believe Larimar Therapeutics is more favorable than Astria Therapeutics.
Astria Therapeutics' return on equity of -35.69% beat Larimar Therapeutics' return on equity.
Summary
Larimar Therapeutics beats Astria Therapeutics on 9 of the 14 factors compared between the two stocks.
Get Astria Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATXS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ATXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Astria Therapeutics Competitors List
Related Companies and Tools
